Life Sciences

  • October 23, 2026

    Teva, Eli Lilly Spar Over Possible New Drug Patent Trial

    Eli Lilly and Teva on Friday sparred over whether a new trial should be held in Massachusetts federal court over the validity of patents related to Teva's migraine drug Ajovy after the Federal Circuit reversed the Boston court's judgment that favored Eli Lilly.

  • October 23, 2026

    Eli Lilly, Novo Nordisk Antitrust Suit Remains Dismissed

    A Texas federal judge has denied Strive Specialties Inc.'s bid to undo her judgment dismissing the compounding pharmacy's lawsuit that accuses Eli Lilly and Novo Nordisk of blocking competition for GLP-1 medications, saying Strive's claim that the court committed a manifest legal error was based on the company's own misunderstanding.

  • October 23, 2026

    Consumers Fight Bids To End Delta-8 Mislabeling Suit

    Vape maker Savage Enterprises, two distributors and a California testing lab must not be allowed to shake a lawsuit accusing them of trying to pass off vape pens with illegal levels of THC as legal hemp products, consumers told an Arkansas federal court, saying their dismissal bids are moot because there is a new complaint.

  • October 23, 2026

    J&J Wins Ohio Talc Mesothelioma Trial

    An Ohio state jury on Friday found in Johnson & Johnson's favor in a wrongful death suit brought by the family of a woman who alleged that her mesothelioma was caused by her longtime use of talc cosmetic products containing asbestos.

  • October 23, 2026

    Del. Forum Selection Clause Sinks IQVIA's NC Poaching Suit

    IQVIA Holdings Inc. should have brought its poaching suit against four former employees accused of defecting to a competitor in Delaware court under a forum selection clause in their employment contracts, a North Carolina Business Court judge ruled Thursday in dismissing the case.

  • October 23, 2026

    Alembic Settles With Vanda Over Schizophrenia Drug Generic

    Vanda Pharmaceuticals and Alembic Pharmaceuticals notified a Delaware federal judge Friday that they have settled a patent dispute over Alembic's planned generic version of Vanda's schizophrenia drug Fanapt.

  • October 23, 2026

    Baxter Says Novum Pump Issues Don't Show Securities Fraud

    A group of Baxter International shareholders should not be allowed to pursue securities fraud claims over a new fluid pump product later deemed defective simply because the product and its revenues performed worse than publicly expected, the company and its executives have told an Illinois federal judge.

  • October 23, 2026

    Generics MDL Judge Won't Extend Pause Over Conflict

    A Pennsylvania federal judge refused Friday to extend a pause on the generic-drug price-fixing multidistrict litigation, eyeing setting a new trial date for the first bellwether case initially paused by a conflict with a special master that the drugmakers say now covers "the entire MDL."

  • October 23, 2026

    Insulet Can't Keep Injunction During Trade Secret Appeal

    The Federal Circuit has denied insulin product developer Insulet Corp.'s request to keep an injunction in place against rival EOFlow Co. Ltd. while it appeals an axed $59 million trade secrets jury verdict to the U.S. Supreme Court.

  • October 23, 2026

    AI Cardiac Imaging Co. Heartflow Files IP Suit Against Rival

    Artificial intelligence-powered cardiac imaging company Heartflow Inc. is accusing a competitor of infringing its patents covering a noninvasive heart test and luring almost a dozen of its employees to make a similar product.

  • October 23, 2026

    Fenwick, Cooley Steer Lycia Therapeutics' Upsized $318M IPO

    Early-stage biotechnology firm Lycia Therapeutics began trading Friday after raising $318 million in its upsized initial public offering steered by Fenwick & West LLP and Cooley LLP.

  • October 23, 2026

    Ultrahuman Sued By Ouraring Again After Redesign Win

    Smart ring-maker Ouraring Inc. has filed another lawsuit against rival Ultrahuman Healthcare Inc., asserting two patents it said were not addressed in an earlier suit that resulted in an import ban that was later lifted when Ultrahuman redesigned its product.

  • October 23, 2026

    Taxation With Representation: Milbank, De Brauw, Wachtell

    In this week's Taxation With Representation, EQT Private Equity announces a takeover offer for life sciences testing company Qiagen NV, Salesforce acquires customer engagement platform Braze and London Stock Exchange Group buys U.S. credit intelligence provider Octus.

  • October 23, 2026

    US Opens Duty Investigations Into Chinese Compounds

    The U.S. Department of Commerce is opening investigations into whether certain chemical compounds imported from China are being sold at less than fair value and are subsidized, the department said Friday.

  • October 22, 2026

    Nestle's Solgar Has Dangerous Vitamin B6 Levels, Suit Says

    Nestle was hit with a proposed false advertising class action Wednesday in New Jersey federal court alleging its Solgar VM-75 supplements contain dangerous levels of vitamin B6, which can heighten the risk of developing peripheral neuropathy or worsen the condition.

  • October 22, 2026

    DEA Judge Will Not Reopen Marijuana Rescheduling Hearing

    The coalition fighting marijuana legalization won a partial victory after a Drug Enforcement Administration's administrative law judge on Thursday allowed into the record a U.S. Government Accountability Office report the group championed but denied new testimony on it, saying the report "speaks for itself."

  • October 22, 2026

    Gilead Reaches $45M Settlement To End Kickback Claims

    The Texas Office of the Attorney General on Thursday announced that pharmaceutical company Gilead Sciences Inc. signed off on a $45 million settlement to end claims that the company ran an illegal kickback scheme in order to get prescribers to favor its medications.

  • October 22, 2026

    Elsevier Beats Defamation Suit Over Air Purifier Article

    An indoor air quality company failed to prove academic publisher Elsevier acted with malice in printing an article questioning the effectiveness of its air purification technology sufficient to sustain a claim for defamation, a North Carolina federal judge ruled Thursday.

  • October 22, 2026

    Full 9th Circ. Won't Review Surgical Robot Antitrust Fight

    The full Ninth Circuit declined to reconsider an appellate panel's recent decision reviving a surgical repair company's antitrust suit alleging Intuitive Surgical blocked third parties from supplying parts for its popular da Vinci surgery robot, according to an order issued Thursday.

  • October 22, 2026

    J&J Says Justices' Denial Backs Tossing Fee Suit At 3rd Circ.

    Johnson & Johnson told the Third Circuit Thursday that the U.S. Supreme Court's recent decision not to take up a group of executives' federal benefits dispute backed its position in an appeal from J&J workers who alleged their health plans were saddled with excessive prescription drug fees.

  • October 22, 2026

    Mylan Settles Connecticut's EpiPen Price Claims For $8M

    Mylan Pharmaceuticals has struck another deal to resolve claims that it illegally inflated prices for EpiPens, this time settling Connecticut state enforcers' allegations of antitrust and consumer protection law violations for $8 million.

  • October 22, 2026

    Purdue Trusts Say Sackler Bid Again Destabilizes Ch. 11 Plan

    The Purdue Pharma bankruptcy trust and trustees for some members of the Sackler family have filed separate documents in a New York bankruptcy court challenging moves they described as continued attempts by Richard S. Sackler and his wife, Lin Gao, to block parts of the drugmaker's bankruptcy plan.

  • October 22, 2026

    10x Genomics Ends Patent Fight Against Parse In Delaware

    10x Genomics has told a Delaware federal judge it will no longer pursue a patent case against Parse Biosciences Inc. over methods of analyzing genetic information, a move following the Federal Circuit's refusal to revive the remaining three patents-at-issue.

  • October 22, 2026

    FTC Wants More Info On Curium's $8B Deal For Lantheus

    The Federal Trade Commission has requested additional information about Curium's planned $8 billion acquisition of fellow radiopharmaceutical company Lantheus Holdings Inc., extending a waiting period that prevents the transaction from closing.

  • October 22, 2026

    Imperative Gets PTAB To Trim Inari Medical Device Claims

    The Patent Trial and Appeal Board has invalidated claims in an Inari Medical Inc. patent on valves used in surgery to prevent blood loss, handing another win to challenger Imperative Care as it fends off an infringement lawsuit in California.

Expert Analysis

  • 3rd Circ. Ruling Opens Door For Fraud-On-The-Market Rethink

    Author Photo

    The Third Circuit's recent decision in Ocugen, holding that a stable stock price after publication of restated financials does not prove immateriality, could be a vehicle for the U.S. Supreme Court to overturn the doctrine undergirding certification of securities class actions, says Jonathan Richman at Brown Rudnick.

  • 5 Issues To Watch As Fed. Circ. Hears Moderna Vax IP Case

    Author Photo

    Upcoming oral arguments before the Federal Circuit in Arbutus v. Moderna will test whether patent liability protections for government contractors extend to vaccines distributed to the public, and the resolution of certain questions, such as how to define “for the government,” may be key to the outcome, say attorneys at Honigman.

  • 6 Ways Biotechs Can Manage Double Patenting Rejection Risk

    Author Photo

    The Patent Trial and Appeal Board review panel’s recent rejection of a Sanofi application signals that biotechnology and pharmaceutical companies should now take steps to mitigate the possibility that their patents may be rejected for obviousness-type double patenting based on the existence of applications filed years later, say attorneys at Sterne Kessler.

  • Series

    Being In The Peace Corps Made Me A Better Lawyer

    Author Photo

    When I served in the Peace Corps, the people of the West African village where I was stationed helped me acclimate to my new surroundings and enabled me to develop problem-solving, teamwork and empathy skills that have bolstered my legal practice far beyond the ability to offer technical advice, says Brian Bewley at McGuireWoods.

  • 6th Circ. Spotlights Cannabis Contract Enforceability Risks

    Author Photo

    The Sixth Circuit's recent reversal of a $31.8 million jury verdict against a subsidiary of cannabis giant Curaleaf highlights that state licenses do not necessarily provide the legal foundation needed to enforce contracts in federal court, which is a pattern that appears across many sectors, say attorneys at ArentFox Schiff.

  • Where DOJ's Fraud Directive May Actually Affect Enforcement

    Author Photo

    The U.S. Department of Justice’s recent directive outlining corporate fraud enforcement priorities is mostly a management document instead of a policy, but one part may actually undermine the directive's goals by leading to worse outcomes for organizational defendants and less corporate self-disclosure, says Zachary Warren at Williams & Connolly.

  • Why Vaccine Court Inoculates Drugmakers Against Litigation

    Author Photo

    Most claimants alleging injuries from routine childhood vaccines must complete an administrative compensation proceeding before they can sue in civil court — and recent legislative efforts aimed at weakening vaccine manufacturers' legal protections do not account for the important reasons the existing framework was put in place, say attorneys at Goldman Ismail.

  • What Lawyers Should Know Before Accepting Crypto Payment

    Author Photo

    As clients increasingly request to pay legal fees, retainers and escrow funds using cryptocurrency, lawyers should consider how only a handful of state bar authorities have addressed the issue with varying ethics opinions, as well as the related questions that no authority has yet answered, says attorney Felix Shipkevich.

  • What To Know As State 'Neural Data' Privacy Laws Emerge

    Author Photo

    Attorneys at Goodwin discuss new state laws aimed at regulating consumer data generated from nervous system activity, explain why neurotechnology is attracting state and federal legislators’ attention, and highlight the compliance obligations that industry players should address now.

  • Data Sale In Spirit Bankruptcy Raises Novel Privacy Risks

    Author Photo

    Spirit Airlines' planned sale of deidentified business data to Google for artificial intelligence training exposes gaps in the Bankruptcy Code's privacy guardrails, particularly for employee information, say attorneys at Patterson Belknap.

  • IDScan Data Breach Puts Spotlight On Vendor Oversight

    Author Photo

    A recently reported breach that exposed millions of identification documents held by IDScan.net highlights the liability risks for businesses that contract with third-party identity processors, and emphasizes the importance of auditing vendors' data retention practices, say attorneys at Tucker Ellis.

  • Series

    Mentalism Makes Me A Better Lawyer

    Author Photo

    Convincing strangers I can read their minds may seem like an unusual second career for a legal practitioner, but both disciplines share several important requirements, including trust and preparation, says Warren Biro at Manatt.

  • Why And How To Build A Neurodiversity-Informed Practice

    Author Photo

    By better understanding neurodiversity and implementing simple accommodations for clients with autism, ADHD or learning differences, attorneys can build stronger relationships with those who may otherwise struggle to obtain and benefit from legal services, while developing good habits that will benefit everyone they represent, says Ting Cheung at Sanford Heisler.

  • Opinion

    PTAB Panels Should Revamp Their IPR Merits Decisions

    Author Photo

    In light of U.S. Patent and Trademark Office Director John Squires' recent announcement about returning merits institution determinations to the Patent Trial and Appeal Board, the implementing framework should strengthen PTAB panels' responsibility for the benefit of both petitioners and patent owners, says Brandon Theiss at AddyHart.

  • Patent Eligibility Bulletin: Claim Solutions, Not Results

    Author Photo

    In the third quarter of the year, two Federal Circuit decisions illustrated that claims sharing the same disclosure can fall on opposite sides of the patent eligibility line, depending on the specific nuances of tech patents' claims, says Reilley Keane at Banner Witcoff.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here